Analysts Issue Forecasts for TARA Q1 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Analysts at Lifesci Capital issued their Q1 2025 earnings estimates for Protara Therapeutics in a research note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will earn ($0.37) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $22.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Lifesci Capital also issued estimates for Protara Therapeutics’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.93) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($2.67) EPS.

Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a report on Thursday, March 6th. Guggenheim reissued a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a report on Friday, December 6th.

Protara Therapeutics Stock Down 0.7 %

NASDAQ TARA opened at $4.07 on Thursday. The stock has a market capitalization of $83.96 million, a P/E ratio of -1.44 and a beta of 1.69. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48. The firm has a 50-day moving average price of $4.49 and a 200 day moving average price of $3.45.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TARA. Janus Henderson Group PLC purchased a new position in Protara Therapeutics in the fourth quarter valued at about $11,938,000. Adage Capital Partners GP L.L.C. purchased a new position in Protara Therapeutics in the fourth quarter valued at about $11,880,000. Toronto Dominion Bank purchased a new position in Protara Therapeutics in the fourth quarter valued at about $11,030,000. Blackstone Inc. purchased a new position in Protara Therapeutics in the fourth quarter valued at about $8,870,000. Finally, RA Capital Management L.P. increased its holdings in Protara Therapeutics by 78.9% in the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after buying an additional 1,500,000 shares in the last quarter. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.